Trial Profile
A Randomised, Open-label Four-way Crossover Study to Evaluate Pharmacokinetics of Salmeterol (Serevent) After Inhalation of a 25 μg and 50 μg Single Dose (Metered Dose Inhaler) and a 50 μg and 100 μg Single Dose (Diskus) in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Salmeterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 09 Oct 2014 New trial record